Arkuda seeks to disrupt the usual progression of neurodegenerative disease with medicines developed by applying cutting-edge knowledge from the domains of lysosomal and microglial biology.
Seismic Therapeutic, Inc. announced its launch and financing of $101 million to fund two new programs and further develop its existing IMPACT™ platform.
Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients.
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
The global women’s health company took another step in its initiative to encourage healthcare equality for women by declaring March 8, International Women’s Day, an annual holiday.
